News

Remap Consulting Educational Series

We are introducing a series over the next few months, for those interested in learning more about pharmaceutical pricing, reimbursement, and market access.

Topics will include:

  • What is Market Access?
  • What is a Payer?
  • IRP – what it is and where to start
  • Benefits of early dialogue with HTA
  • What are Managed Entry Agreements?
  • What is EMA HTA parallel consultation?

This months’ topic is ‘What is Market Access’ and covers how important having a robust market access strategy in place is for the successful launch of a product.

What is Market Access?

Market access is a broad term that is used to describe activities and processes that pharmaceutical and biotech companies undertake to secure a reimbursed price, which reflects the product’s value for the broadest possible patient population within the shortest feasible timeframe.

In order to deliver commercial success, a good market access strategy is required which identifies the product’s value from a payer […]

By |2020-02-20T09:18:05+00:00February 20th, 2020|News|Comments Off on Remap Consulting Educational Series

How likely are drug price reductions in the US and could they lead to price increases in Europe and the rest of the world?

Prescription drug prices in the US continually rank among the highest in the world. According to a report by the OECD, the US spent $1220 on pharmaceuticals per capita in 2017. This compares to $823 in Germany, $469 in the UK and $391 in the Netherlands(1)Health care costs make up 52% of consumer credit(2) and many patients report that significant out-of-pocket costs forces the self-rationing of their medicineswith severe consequences for their health(3). It is therefore not surprising that the high cost of branded medicines has become a potent political issue in the USAnd whilst on the surface this may appear to be a domestic issue, the rest of the world may wish to take note.  

American Patients First 

Prescription drug pricing reduction was one of […]

By |2020-02-14T17:13:50+00:00February 14th, 2020|News|Comments Off on How likely are drug price reductions in the US and could they lead to price increases in Europe and the rest of the world?

Westminster Health Forum – the future for NICE in health and social care

The Westminster Health Forum organise senior level conferences on public policy relating to health and healthcare issues. The session on Thursday 6th February was titled ‘The future for NICE in health and social care’ and whilst NICE and NICE processes were at the centre of discussions, the key theme running throughout the morning was that of collaboration and the patient voice. 

The message was clear: NICE want to say yes to medicines that will benefit patients but this requires the right data and collecting that data needs to be a collaboration between industry, academics, patients and doctors. This was highlighted by the case of the FDA’s accelerated approvals programme. Only 20% of products with accelerated approval have shown benefit in confirmatory trials meaning resources have been directed away from effective treatments to pay for these ultimately ineffective ones. Whilst NICE want to bring effective, innovative medicines […]

By |2020-02-27T09:09:16+00:00February 13th, 2020|News|Comments Off on Westminster Health Forum – the future for NICE in health and social care

Remap Pedometer Challenge

12 days into our Pedometer Challenge and the Remap team have done 795,108 steps, or approximately 375 miles. This means we have now crossed the English Channel and are just outside Rouen on our route down to Zug in Switzerland (and back)!

We are walking all this way to help raise money for the East Cheshire Hospice, a local hospice that provides care, comfort and compassionate support to those with life-limiting illnesses. To make a donation to the ECH in support of our challenge, please click on the link here; anything you can give would be greatly appreciated!

By |2020-02-12T15:13:58+00:00February 12th, 2020|News|Comments Off on Remap Pedometer Challenge

Hannah Lorquet at Westminster Health Forum

Hannah is attending a conference at the Westminster Health Forum today on:

The future for NICE in health and social care.

Lady wearing glasses

If you need help with a NICE submission, market access, pricing and reimbursement, or training on real world evidence please contact us.

By |2020-02-06T09:22:29+00:00February 6th, 2020|News|Comments Off on Hannah Lorquet at Westminster Health Forum

Pedometer Challenge for the East Cheshire Hospice

The team at Remap Consulting would like to raise some much-needed cash for the East Cheshire Hospice who provide care, comfort and compassionate support to those with life-limiting illnesses – a worthy cause which is very close to our hearts.

We are aiming to complete enough steps in February which will reach from our offices in Cheshire, via our affiliate office in Bristol all the way to our headquarters in Switzerland!

This equates to 5 miles per day for each team member which we think you’ll agree is no mean feat 😲

route from cheshire via bristol to switzerland

If you would like to help us by contributing to our JustGiving page, please click on this link.

By |2020-01-30T16:19:10+00:00January 31st, 2020|News|Comments Off on Pedometer Challenge for the East Cheshire Hospice

Third Annual Enterprise Alumni event at Manchester University

Fatima Chunara and Alvaro San Martin will be attending the third annual enterprise alumni event at Manchester University today.

The event runs from 5pm-7pm and they will be providing post-graduate students with insights into Market Access and answering any questions they have with regards a career within the industry.

Fatima & Alvaro

 

 

By |2020-03-12T16:28:40+00:00January 31st, 2020|News|Comments Off on Third Annual Enterprise Alumni event at Manchester University

NICE-EMA scientific advice in a post-Brexit era: what offerings will be available?

NICE has for, a number of years (and currently continues to), provided scientific advice and HTA early dialogue to manufacturers through the EMA HTA parallel consultation process (in partnership with the EMA and other HTA bodies). However, with the UKs upcoming withdrawal from the European Union, NICE’s relationship with EMA and indeed, the parallel scientific advice process is uncertain.

As it is unlikely that NICE will continue to offer scientific advice as part of the parallel scientific advice procedure, one option for manufacturers is to utilize NICE’s European HTA and regulatory concurrent advice service.

The concurrent scientific advice process works alongside EMA timelines and requires submission of the same briefing book provided to the EMA. Both NICE and the EMA will assess the briefing book separately and the company will receive two separate list of issues from each stakeholder, respectively.

NICE then offers manufacturers two options:

By |2020-02-05T09:02:46+00:00January 30th, 2020|News|Comments Off on NICE-EMA scientific advice in a post-Brexit era: what offerings will be available?

Graham presenting at Regulanet®annual conference this Thursday

Graham is delighted to be presenting on the subjects of Health Technology Assessments and Regulatory – Parallel scientific advice experiences and the proposed EMA joint HTA assessment process at the Regulanet® annual conference in Germany on Thursday 30th January.

If this is an area that you feel you could benefit from expert advice, please don’t hesitate to contact us.

By |2020-01-24T17:33:47+00:00January 28th, 2020|News|Comments Off on Graham presenting at Regulanet®annual conference this Thursday